Swarm Immunization with CH505 Envelopes for bnAb Induction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HIV-1 vaccine development has not successfully induced high levels of broadly neutralizing antibodies (bnAbs), which are crucial for protecting against HIV infection, as existing vaccines fail to recreate the antigenic evolution of viruses that occur during bnAb generation in vivo.
Innovation Solution
The development of immunogenic compositions comprising 'swarms' of sequentially evolved HIV-1 envelope proteins and nucleic acids, specifically selected to mimic the antigenic evolution that leads to bnAb induction, including the use of CH505 envelope variants as primes and boosts, with adjuvants and immune modulators to enhance immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing vaccines are used, then vaccination can be administered, but they fail to induce high levels of broadly neutralizing antibodies
Solution Approach 1:
The vaccine composition uses dynamically evolving envelope protein swarms that change over time to mimic natural viral evolution, allowing the immune system to develop progressively broader neutralizing antibody responses through sequential immunization with evolving viral variants
Solution Approach 2:
The invention changes the parameters of envelope protein diversity and evolutionary trajectory by using computationally designed swarms with controlled genetic variation, enabling the induction of high levels of bnAbs through optimized antigenic evolution that differs from natural infection patterns
2Ease of manufacture
If single envelope proteins are used in vaccines, then the composition is simple to manufacture, but they cannot induce cross-reactive neutralizing antibodies with broad coverage
Solution Approach 1:
The vaccine divides the envelope protein immunogen into multiple discrete variants within a swarm, each representing different stages of viral evolution, allowing the immune system to be exposed to diverse epitopes that collectively induce broad cross-reactive neutralizing antibody responses
Solution Approach 2:
The invention creates a composite vaccine composition by combining multiple envelope protein variants with different genetic sequences and antigenic properties, forming a swarm that collectively provides broad neutralizing antibody induction while maintaining manufacturability through standardized production protocols
3Device complexity
If vaccines do not recreate antigenic evolution, then the development process is straightforward, but they fail to induce bnAbs that occur in vivo
Solution Approach 1:
The invention performs preliminary computational design of envelope protein swarms to pre-establish the antigenic evolution pathway that will occur during vaccination, allowing the immune system to follow a controlled evolutionary trajectory that replicates in vivo bnAb generation without requiring complex live viral passages
Solution Approach 2:
The vaccine creates a simplified copy of the natural viral evolution process by using computationally designed envelope protein variants that mimic the antigenic changes occurring during chronic infection, enabling bnAb induction through controlled replication of evolutionary patterns without requiring actual viral propagation
Data Source
AI summary
In certain aspects the invention provides HIV-1 immunogens, including envelopes (CH505) and selections therefrom, and methods for swarm immunizations using combinations of HIV-1 envelopes.